Form 8-K - Current report:
SEC Accession No. 0001193125-25-048426
Filing Date
2025-03-06
Accepted
2025-03-06 16:16:12
Documents
15
Period of Report
2025-03-06
Items
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d925111d8k.htm   iXBRL 8-K 25012
2 EX-99.1 d925111dex991.htm EX-99.1 54989
6 GRAPHIC g925111g0306195720402.jpg GRAPHIC 2585
  Complete submission text file 0001193125-25-048426.txt   217851

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA avir-20250306.xsd EX-101.SCH 2859
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE avir-20250306_lab.xml EX-101.LAB 17994
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE avir-20250306_pre.xml EX-101.PRE 11267
17 EXTRACTED XBRL INSTANCE DOCUMENT d925111d8k_htm.xml XML 3640
Mailing Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110
Business Address 225 FRANKLIN STREET SUITE 2100 BOSTON MA 02110 857-204-8109
Atea Pharmaceuticals, Inc. (Filer) CIK: 0001593899 (see all company filings)

EIN.: 460574869 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-39661 | Film No.: 25715455
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)